| |
| Monday, March 7, 2011 |
|
China AIDS vaccine programs on-course, early candidate phase 1 completed
|
|
Anti-obesity drug orlistat continues to receive heavy attention for ADRs
|
|
Poniard Pharma gets SFDA nod for pair of Phase 3 anti-cancer drug trials
|
| |
 |
| |
| Friday, March 4, 2011 |
|
S&P Pharma plans pre-transplant in-vitro diagnostics JV
|
|
MOH coughs up 8 new clinical pathways for respiratory indications
|
|
CAMS to top China leadership: More SFDA reviewers and staff needed
|
| |
|
| |
| Thursday, March 3, 2011 |
|
11th 5yr plan credited with 16 new drugs and more on the way
|
|
Prices going south up north- Heilongjiang drops EDL prices by 38%
|
|
China vaccine regulatory system passes WHO standards
|
|
Tsinghua University opens new Institute for Clinical Neuroscience
|
|
MOH releases 2011 guideline for the management of influenza
|
| |
|
| |
| Wednesday, March 2, 2011 |
|
Jiangxi Renhe gears up for local acquisitions via private placement
|
|
Fosun plans H-share listing
|
|
Here today, Gan tomorrow: Tonghua Dongbao to sell stake in Gan & Lee
|
| |
|
| |
| Tuesday, March 1, 2011 |
|
Wuhan Wuchang Hospital to drop prices of 360 drugs by 3%
|
|
Beijing FDA sets up public website to monitor zero markups of EDL drugs
|
|
Shanghai forms rare disease dep't to aid legislation,insurance coverage
|
|
Shenzhen aims to set up 1 tier 3 public hospital per district by 2015
|
|
Beijing 2010 crackdown on illegal medical practitioners hits nearly 2k
|
| |
|
| |
| Monday, February 28, 2011 |
|
SFDA grants OTC status to 54 prescription drugs, majority are TCMs
|
|
Guangdong: Dongguan Hospital to drop drug prices by 20% with M&A deal
|
|
Qingdao Huaren receives SFDA clearances for 2 urological solutions
|
|
Zhejiang Hisoar to raise RMB 520 m for carbapenem/clindamycin projects
|
| |
|
| |
| Friday, February 25, 2011 |
|
MOH issues glucocorticoids clinical application guideline
|
|
Shanghai Pharma Holding,Fudan-Zhangjiang to develop Duotibofen,3 others
|
| |
